Monte Rosa Therapeutics, Inc. GLUE Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $123.67M+63.5% | $75.62M— | $0— | —— | ||
| $141.5M+16.4% | $121.56M+9.2% | $111.27M+30.8% | $85.06M+48.8% | ||
| $36.38M+3.4% | $35.17M+9.8% | $32.04M+17.3% | $27.32M+73.7% | ||
| $177.88M+13.5% | $156.73M+9.4% | $143.31M+27.5% | $112.38M+54.2% | ||
| $177.88M+13.5% | $156.73M+9.4% | $143.31M+27.5% | $112.38M+54.2% | ||
| -$54.21M— | —— | -$143.31M-27.5% | -$112.38M-54.2% | ||
| -43.8%— | —— | —— | —— | ||
| $12.94M+22.5% | $10.57M+13.2% | $9.33M+148% | $3.76M+8,083% | ||
| $14.49M+31.9% | $10.98M+32.4% | $8.3M+114% | $3.88M+461% | ||
| $59K— | $0-100% | $24K-78.0% | $109K— | ||
| -$39.72M— | —— | -$135.01M-24.4% | -$108.5M— | ||
| -$1.16M-145% | $2.57M+614% | $360K— | $0— | ||
| -$38.6M— | —— | -$135.35M-24.7% | -$108.5M-46.7% | ||
| -31.2%— | —— | —— | —— | ||
| -$0.46— | —— | -$2.63-14.8% | -$2.29— | ||
| 330.6M+15.1% | 287.3M+43.7% | 200M+6.8% | 187.2M+141% | ||
| 329.8M+14.8% | 287.3M+43.7% | 200M+6.8% | 187.2M— | ||
| $12.94M+22.5% | $10.57M+13.2% | $9.33M+148% | $3.76M+8,083% | ||
| -$0.46— | —— | -$2.63-14.8% | -$2.29— | ||
| -$0.46— | —— | -$2.63-14.8% | -$2.29— | ||
| -$39.1M— | —— | -$136.32M-26.0% | -$108.23M-44.5% | ||
| —— | —— | -$397K— | —— | ||
| $1.53M+269% | $416K+145% | -$930K— | —— | ||
| $59K— | $0-100% | $24K-78.0% | $109K— | ||
| —— | —— | —— | —— | ||
| -$54.21M— | —— | -$143.31M-27.5% | -$112.38M-54.2% | ||
| -$45.85M— | —— | -$137.09M-26.2% | -$108.64M-53.4% | ||
| -$45.85M— | —— | -$137.09M-26.2% | -$108.64M-53.4% | ||
| -37.1%— | —— | —— | —— | ||
| -$54.21M— | —— | -$143.31M-27.5% | -$112.38M-54.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Monte Rosa Therapeutics, Inc.'s revenue?
- Monte Rosa Therapeutics, Inc. (GLUE) generated $43.0M in revenue over the trailing twelve months, down 73.1% year over year.
- Is Monte Rosa Therapeutics, Inc. profitable?
- Monte Rosa Therapeutics, Inc. is not currently profitable: it reported a net loss of $130.0M over the trailing twelve months, a -302.6% net margin.
- What is Monte Rosa Therapeutics, Inc.'s earnings per share?
- Monte Rosa Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-1.48.
- Where does Monte Rosa Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Monte Rosa Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
